Secale Cereale Pollen
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
SECALE CEREALE POLLEN: From Unknown Indication to Alopecia
One-Sentence Summary
Secale cereale pollen (rye pollen extract) has no recorded original indication in current data, and is not marketed in Taiwan. The TxGNN model predicts it may be effective for Alopecia, but this prediction is currently supported by 0 clinical trials and 0 publications, with no identifiable mechanistic pathway.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no licenses on record) |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.01% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Secale cereale (rye) pollen extract is traditionally associated with allergen testing and allergen-specific immunotherapy use, but no original indication is recorded in this evidence pack, and the drug is not currently marketed in Taiwan.
There is no identifiable biological pathway connecting a pollen allergen extract to alopecia (hair loss) — mechanisms relevant to alopecia typically involve follicular growth signaling, androgen metabolism, or localized inflammatory/autoimmune processes (e.g., alopecia areata), none of which have an established link to pollen allergen exposure or immunotherapy.
The high TxGNN score (0.99) most likely reflects an indirect graph association — for example, shared immune/inflammatory pathway nodes in the knowledge graph — rather than a direct pharmacological mechanism. Given the complete absence of supporting clinical or literature evidence, this prediction cannot currently be distinguished from graph noise or a false positive arising from sparse node connectivity.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No marketing authorizations on record — this drug is not currently marketed (未上市) with 0 licenses in the dataset.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction is based solely on a TxGNN model score with no supporting clinical trials, literature, mechanism of action data, or plausible biological rationale — the evidence level is L5 (model prediction only). Combined with the drug’s unmarketed status in Taiwan and blocking data gaps in safety information, this candidate does not meet the threshold to advance.
To proceed, the following is needed:
- Mechanism of action (MOA) data from DrugBank or primary literature
- Original indication history to establish pharmacological plausibility
- TFDA label warnings/contraindications (currently blocking — DG001)
- At least preclinical or mechanistic literature linking rye pollen extract to hair follicle biology before further evaluation is warranted
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.